Board of Directors

Dr. Dahiyat has been Xencor’s president and chief executive officer since the Company’s incorporation in August 1997, and is the co-founder of Xencor, and co-inventor of Xencor’s breakthrough XmAb® technology.  He has lead the Company in raising over $240 million in public and private financing and in establishing a diverse portfolio of monoclonal antibody clinical programs for the treatment of life-threatening and debilitating diseases.

Dr. Dahiyat holds a Ph.D. in Chemistry from Caltech and B.S. and M.S.E. degrees in Biomedical Engineering from the Johns Hopkins University.  He has co-authored numerous scientific papers in the fields of protein design and drug delivery, is an inventor of 32 US and numerous foreign patents, and has received scientific awards from the American Chemical Society, the Controlled Release Society, the Protein Society and Caltech.

Dr. Carter was appointed Chairman of the Board of Xencor, Inc. in December 2009. In November 2009, he joined Immune Design Corp. where he serves as Executive Chairman of the Board. In addition to his duties at Immune Design, Dr. Carter serves as Chairman of the Board at the TB Alliance, and is a member of a number of other Boards, including Moksha8, QLT, Inc., and Dr. Reddy’s Lab. Prior to joining Immune Design, Dr. Carter was a member of the management team at ZymoGenetics, Inc. where he held various positions, including Chief Executive Officer from April 1998 to January 2009. Dr. Carter first joined ZymoGenetics in 1986 as Vice President of Research and Development. In 1988 Novo Nordisk A/S acquired ZymoGenetics and, in 1994, Dr. Carter was promoted to Corporate Executive Vice President and Chief Scientific Officer for Novo Nordisk. In 2000, Dr. Carter led the negotiations that established ZymoGenetics as an independent company from Novo Nordisk. As CEO, he was instrumental in transforming ZymoGenetics from the research arm of a European biopharmaceutical company to a company that developed and commercialized Recothrom®. Dr. Carter also held various positions of increasing responsibility at G.D. Searle & Co., Ltd. from 1982 to 1986 and was a Lecturer at Trinity College, University of Dublin from 1975 to 1982. He received a B.Sc. with Honors in Botany from the University of Nottingham, England, and a Ph.D. in Microbiology from Queen Elizabeth College, University of London.

Robert F. Baltera, Jr. is a seasoned pharmaceutical industry executive and board member of several healthcare companies. Mr. Baltera currently serves as an entrepreneur-in-residence at the venture capital firm of Frazier Healthcare Partners and is chief executive officer of Hawkeye Therapeutics, a company funded by Frazier Healthcare.  In 2015, he served as chief executive officer and a member of the board of directors of Laguna Pharmaceuticals, a private biopharmaceutical company. From 2007 to 2011, he was the chief executive officer of Amira Pharmaceuticals, which was acquired by Bristol-Meyers Squibb Company in 2011. He was instrumental in focusing Amira's development efforts, strengthening its pipeline and forging key collaborations with partners such as GlaxoSmithKline.  Prior to Amira, Mr. Baltera worked for 17 years at Amgen, during which time he held a number of senior management positions, the last being vice president of corporate and contract manufacturing. Mr. Baltera served as the team leader responsible for the approval of Kineret™ in rheumatoid arthritis, a highlight of his many accomplishments while at Amgen.

Mr. Baltera serves in senior roles in several organizations, including as a member of the board of directors of Organovo Holdings (ONVO), Panmira Pharmaceuticals, Ruga Corporation and the San Diego Venture Group, and as a member the Board of Trustees of the Keck Graduate Institute.  Mr. Baltera has an M.B.A. from the Anderson School at UCLA and earned his B.S. in microbiology and a M.S. in genetics from The Pennsylvania State University.  In 2013 Mr. Baltera was awarded the Eberly College of Science (Pennylvania State University) Outstanding Alumni Award.

Mr. Gustafson has more than 25 years of diverse experience in corporate finance, with 15 years in senior management roles leading the finance departments of multi-faceted, dynamic and growth oriented biopharmaceutical industry organizations. Currently, Mr. Gustafson serves as executive vice president, chief financial officer and principal accounting officer at Spectrum Pharmaceuticals, Inc. Prior to that, he served as chief financial officer at Halozyme Therapeutics, Inc., a publicly-traded biopharmaceutical company, where he managed several successful financings and established a three year mid-range planning process to align resource allocations to long term strategic goals. Before Halozyme, Mr. Gustafson worked at Amgen for over 18 years, most recently as vice president, finance, with responsibility for financial planning and cost accounting for worldwide manufacturing covering seven manufacturing sites. During his tenure at Amgen, Mr. Gustafson also served as treasurer, vice president, finance and chief financial officer of Amgen International based in Switzerland. Mr. Gustafson holds a B.A. degree in accounting from North Park University in Chicago and an M.B.A. from University of California, Los Angeles.

A. Bruce Montgomery, M.D., has more than 25 years of drug development, operations and financing experience, including positions at Genentech, Inc., Pathogenesis Corporation, Corus Pharma, and Gilead Sciences, Inc. He is currently Chief Executive Officer and member of the board of Cardeas Pharma, a company he founded in 2010. Prior to founding Cardeas, Dr. Montgomery served 4 years as Senior Vice President of Gilead and 6 years as Chief Executive Officer of Corus Pharma, a specialized biotechnology company that he founded, and which was acquired by Gilead in 2006. While at Gilead, Dr. Montgomery successfully led the development of Cayston (aztreonam) as a treatment for cystic fibrosis patients. Dr. Montgomery also served as Executive Vice President of Research and Development at PathoGenesis Corporation until its acquisition by Chiron Corporation in 2000. He has served as a board member for ZymoGenetics,  Inc. and is currently on the board of Alder Biopharmaceuticals and Cytodyn, Inc.  Dr. Montgomery is a board certified internist and pulmonologist. Montgomery received his B.S. in Chemistry (Magna cum Laude, Outstanding Chemistry Major [Merck Award]), and M.D. (Alpha Omega Alpha Honor Medical Society) from the University of Washington, Seattle.

Mr. Hata has more than 20 years of biotechnology company experience. Since August 2015 he has served as co-founder, chief executive officer and member of the board of directors of IDEAYA Bioscienses, a private oncology company.  In 2015, Mr. Hata served as chief operating officer at immune-oncology company, FLX Bio, where he oversaw all business operations, mergers and acquisitions, and licensing.   Prior to that Mr. Hata served as chief operating officer at immuno-oncology companies, Flexus Biosciences and spinout FLX Bio, until Flexus Biosciences’ acquisition by Bristol-Meyers Squibb in April 2015.  From 2010 until its acquisition by Amgen in October 2013, Mr. Hata was vice president, corporate development and strategy at Onyx Pharmaceuticals, where he held various leadership roles, including head of mergers and acquisitions, and licensing, and head of corporate strategy and strategic asset management. From 2002 to 2010, he served in various roles as vice president, senior vice president, and chief business officer at Enanta Pharmaceuticals, and earlier in his career served in business and corporate development roles at Genome Therapeutics Corporation, McKinsey and Company and ImClone Systems Incorporated. Mr. Hata obtained his M.B.A. at Wharton as a Henry J. Kaiser recipient and completed undergraduate studies in chemistry at Oxford University and Colorado College. Mr. Hata serves on the board of visitors of the Moores Cancer Center, at the University of California, San Diego.